MG treatments should continue during COVID-19 infection: Study
The use of myasthenia gravis (MG) treatments did not increase COVID-19 infection risk or severity, according to a new…
Articles by Katherine Poinsatte, PhD
Phase 3 trial of oral cladribine for generalized MG doses first patient
The first patient has been dosed in a Phase 3 clinical trial that’s assessing the safety and efficacy of oral…
Vyvgart, steroid therapy used as treatment for myasthenic crisis
Combining Vyvgart (efgartigimod) with steroid therapy resolved a myasthenic crisis, a potentially life-threatening complication of myasthenia gravis (MG)…
Serious breathing difficulties lead to MG diagnosis in woman, 41
Serious breathing difficulties, called acute respiratory distress, was the initial clinical manifestation of myasthenia gravis (MG) in a 41-year-old…
Muscles controlling eye movements smaller in MG patients: Study
The volume of the extraocular muscles controlling eye movements is decreased in Chinese patients with myasthenia gravis (MG), particularly…
Rituximab treats myasthenia gravis patients with anti-MuSK antibodies
Rituximab effectively treated most myasthenia gravis (MG) patients who were positive for antibodies against muscle-specific tyrosine kinase (MuSK),…
Many spend more than a year waiting for gMG diagnosis: Study
More than a quarter of patients with generalized myasthenia gravis (gMG) spend more than a year waiting for an…
Experimental cell therapy KYV-101 wins RMAT designation for MG
Kyverna Therapeutics’ experimental cell therapy, KYV-101, has been granted regenerative medicine advanced therapy (RMAT) status by the U.S. Food…
Better thymectomy outcomes with mild generalized myasthenia gravis
Patients with generalized myasthenia gravis (gMG) with mild pre-surgery muscle weakness had more favorable outcomes after a thymectomy,…
1st US patient enrolled in Phase 3 trial of gMG therapy telitacicept
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept to…